32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody.

Background: We previously showed that bortezomib (BTZ) partially depletes plasma cells, yet has limited efficacy for desensitization in kidney transplant candidates when up to 16 doses is given. Methods: This study aimed to determine the safety and efficacy of 32 doses of BTZ (1.3 mg/m2 of body surface area) in 10 highly sensitized kidney transplant candidates with alloantibodies against their intended living donor. Results: Dose reduction was needed in 2 patients and 2 others completely discontinued therapy for adverse events. Anti-HLA antibodies mean fluorescence intensity (MFI) values were stable prior to BTZ (P = 0.96) but decreased after therapy (mean decrease of 1916 [SE, 425] MFI, P

from #ENT via xlomafota13 on Inoreader http://ift.tt/29pL0GT
via IFTTT